Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02616393
Recruitment Status : Completed
First Posted : November 26, 2015
Last Update Posted : January 21, 2020
Sponsor:
Information provided by (Responsible Party):
Kadmon Corporation, LLC

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : January 17, 2019
Actual Study Completion Date : January 17, 2019
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 May 28, 2021